Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
534 results
  • Neuropsychiatric Events Associated with Leukotriene-Modifying Agents: A Systematic Review. [Review]
  • DSDrug Saf 2017 Oct 26
  • Law SWY, Wong AYS, … Chan EW
  • CONCLUSIONS: The risk of NEs was not quantified, because of the lack of randomized controlled trials and observational studies investigating the association.Many pharmacovigilance studies have been conducted to determine the association between NEs and LTMAs, but there is limited evidence from observational studies. High-quality epidemiological studies should be conducted to evaluate the association and quantify the risk, not only in children, but also in adults.
  • The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field. [Review]
  • EJEur J Clin Pharmacol 2017; 73(7):799-809
  • Hoxha M, Rovati GE, Cavanillas AB
  • CONCLUSIONS: What it is known about leukotriene receptor antagonists? •Leukotriene receptor antagonist, such as montelukast and zafirlukast, is used in asthma, COPD, and allergic rhinitis. • Montelukast is the most prescribed CysLT1antagonist used in asthmatic patients. • Different in vivo animal studies have shown that leukotriene receptor antagonists can prevent the atherosclerosis progression, and have a protective role after cerebral ischemia. What we still need to know? • Today, there is a need for conducting clinical trials to assess the role of montelukast in reducing cardiovascular risk and to further understand the mechanism of action behind this effect.
New Search Next